Table III.
Comparisons of STI testing history and recency of testing by use of PrEP among sexually active cisgender men and transgender women who have sex with men (N = 129)
| Never PrEP | Ever PrEP | Chi-square Test Statistic (p)* | |||||
|---|---|---|---|---|---|---|---|
| N = 83 | N = 46 | ||||||
| N 1 | % | n 1 | % | n 1 | % | ||
| Any STI | |||||||
| Ever testeda | 111 | 86% | 67 | 81% | 44 | 96% | 5.5 (.019) |
| Recently testedb | 78 | 61% | 39 | 47% | 39 | 85% | 17.7 (<.001) |
| Last tested >1 year agoc | 33 | 26% | 28 | 42% | 5 | 11% | 11.8 (.001) |
| HPV | |||||||
| Ever testeda | 38 | 30% | 15 | 18% | 23 | 50% | 14.5 (<.001) |
| Recently testedb | 20 | 16% | 6 | 7% | 14 | 30% | 12.2 (<.001) |
| Last tested >1 year agoc | 18 | 14% | 9 | 60% | 9 | 39% | 1.6 (.208) |
| Genital warts | |||||||
| Ever testeda | 29 | 23% | 15 | 18% | 14 | 30% | 2.6 (.107) |
| Recently testedb | 22 | 17% | 12 | 15% | 10 | 22% | 1.1 (.292) |
| Last tested >1 year agoc | 7 | 5% | 3 | 20% | 4 | 29% | FET (.682) |
| Herpes | |||||||
| Ever testeda | 59 | 46% | 29 | 35% | 30 | 65% | 10.6 (.001) |
| Recently testedb | 38 | 30% | 16 | 20% | 22 | 48% | 11.3 (.001) |
| Last tested >1 year agoc | 21 | 16% | 13 | 45% | 8 | 27% | 2.1 (.145) |
| Chlamydia | |||||||
| Ever testeda | 81 | 63% | 39 | 47% | 42 | 91% | 24.9 (<.001) |
| Recently testedb | 57 | 44% | 19 | 23% | 38 | 83% | 42.8 (<.001) |
| Last tested >1 year agoc | 24 | 19% | 20 | 51% | 4 | 10% | 16.9 (<.001) |
| Gonorrhea | |||||||
| Ever testeda | 85 | 66% | 45 | 55% | 40 | 87% | 13.6 (<.001) |
| Recently testedb | 56 | 44% | 21 | 26% | 35 | 76% | 30.5 (<.001) |
| Last tested >1 year agoc | 29 | 23% | 24 | 53% | 5 | 13% | 15.7 (<.001) |
| Hepatitis B | |||||||
| Ever testeda | 74 | 58% | 37 | 45% | 37 | 80% | 15.1 (<.001) |
| Recently testedb | 47 | 37% | 18 | 22% | 29 | 63% | 21.4 (<.001) |
| Last tested >1 year agoc | 27 | 21% | 19 | 51% | 8 | 22% | 7.1 (.008) |
| Hepatitis C | |||||||
| Ever testeda | 72 | 56% | 36 | 43% | 36 | 78% | 14.6 (<.001) |
| Recently testedb | 49 | 38% | 19 | 23% | 30 | 65% | 22.5 (<.001) |
| Last tested >1 year agoc | 23 | 18% | 17 | 47% | 6 | 17% | 7.7 (.005) |
| Syphilis | |||||||
| Ever testeda | 80 | 62% | 37 | 45% | 43 | 94% | 30.0 (<.001) |
| Recently testedb | 55 | 43% | 18 | 22% | 37 | 80% | 41.8 (<.001) |
| Last tested >1 year agoc | 25 | 19% | 19 | 51% | 6 | 14% | 12.9 (<.001) |
| Trichomoniasis | |||||||
| Ever testeda | 20 | 16% | 11 | 13% | 9 | 20% | 1.0 (.315) |
| Recently testedb | 15 | 12% | 6 | 7% | 9 | 20% | 4.6 (.032) |
| Last tested >1 year agoc | 5 | 4% | 5 | 46% | 0 | 0% | FET (.038) |
Ns may not sum to 129 due to missing data. Percents are of those with non-missing data.
Compared to respondents who never tested
Compared to respondents who have not tested recently (i.e., never tested or last tested more than a year ago)
Compared to respondents who have tested recently
For cell counts < 5, Fisher’s exact tests (FET) include a significance level without a test statistic